Excellent Results Received from GeoVax's Full-Dose HIV/AIDS Vac... ( ATLANTA Nov. 2 /- GeoVax Labs Inc...)

Excellent Results Received from GeoVax's Full-Dose HIV/AIDS Vaccine Trial

Date:11/2/2007

ATLANTA, Nov. 2 /PRNewswire-FirstCall/ -- GeoVax Labs, Inc. (OTC Bulletin Board: GOVX), an Atlanta based biotechnology company, announced today excellent safety and immunogenicity data from its full-dose HIV/AIDS vaccine human trial which began in September 2006.

This full-dose trial is the second in a series of four Phase 1 human trials designed to test the safety and immunogenicity of the GeoVax HIV/AIDS vaccines. Involving 36 participants of which 30 received vaccine and 6 received placebo, this trial protocol included vaccination with two full-doses of GeoVax's DNA vaccine to prime the immune response followed by two full- doses of GeoVax's MVA vaccine to boost the immune response. GeoVax's DNA and MVA vaccines express over 50% of the AIDS virus (HIV-1) protein components in order to stimulate a broad anti-HIV immune response. The vaccines cannot cause AIDS because they do not include complete virus. A Phase 1 human trial, started in April 2006, evaluated the delivery of only 1/10th of the full dosage and utilized the same vaccine regimen evaluated in the full dose trial.

From data collected from the 26 participants who completed the trial, the following positive conclusions were observed:

-- GeoVax HIV/AIDS vaccines, both DNA and MVA, continue to demonstrate that they are quite safe and immunogenic following the delivery of the four full-doses (two of each vaccine) used in the trial's protocol

-- The full-dose regimen of GeoVax vaccines continues to be well tolerated without any type of reaction, mild or systemic, in the majority of participants

-- CD4 T-cell and CD8 T-cell responses are very evident both in the 1/10th dose and full-dose vaccine recipients

-- Antibody responses to the envelope glycoprotein (Env) increased following the fourth vaccination, and were present in 88% of the full-dose participants

-- Delivery of the fourth vaccination increased the frequency and magnitude of the CD8 T-cell and Antibody
'/>"/>

SOURCE GeoVax Labs, Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4
Related medicine technology :

1. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
2. Largest Cervical Cancer Vaccine Efficacy Trial Shows Cervarix Provides Excellent Protection Against Lesions Caused by Most Common Cancer-Causing Virus Types
3. Avant’s Typhoid Fever Vaccine Demonstrates Excellent Clinical Potential
4. Avants Typhoid Fever Vaccine Demonstrates Excellent Clinical Potential
5. Point of Care Cardiac Analyzers Yield Rapid Cardiac Marker Results
6. Diagnosing Diabetes: Immediate HbA1c Results Improve Glycemic Control
7. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
8. Sygnis Pharma AG announces date for presentation of clinical results
9. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
10. Positive Aggrastat Results Featured in the Journal of the American College of Cardiology
11. Pixantrone Combination Therapy for First-line Treatment of Aggressive Non-Hodgkins Lymphoma Results in Reduction in Severe Toxicities Including Heart Damage When Compared to Doxorubicin-based Therapy

Post Your Comments:

(Date:12/16/2009)... Dec. 16 Medlytix, a national healthcare ... a key half-billion dollar milestone - the total ... provided in financial assistance to more than a ... of properly classifying charity care - in less ... of these hospitals enhanced their bottom lines and ...

(Date:12/16/2009)... Incorporated (Nasdaq: ARAY ), a global leader in ... and chief executive officer, Euan S. Thomson, Ph.D., is ... Healthcare Conference in San Francisco on Wednesday, January 13, ... A live webcast of each presentation will be available ... Web site at http://www.accuray.com . The webcast ...

(Date:12/16/2009)... A new application developed by American ... of specialty pharmaceuticals has increased health plan staff ... reducing costs. ,, AIM, a leading diagnostic imaging ... clients representing over 35 million consumers and an ... WLP ), adapted the successful clinical and technology ...

Breaking Medicine Technology:Healthcare Scoring System Allows Hospitals To Increase Charity Care 2 Healthcare Scoring System Allows Hospitals To Increase Charity Care 3 Healthcare Scoring System Allows Hospitals To Increase Charity Care 4 Accuray Incorporated to Present at 28th Annual J. P. Morgan Healthcare Conference 2 American Imaging Management's New Specialty Drug Program Delivers Immediate Results 2 American Imaging Management's New Specialty Drug Program Delivers Immediate Results 3 American Imaging Management's New Specialty Drug Program Delivers Immediate Results 4 New Website Offers Free Tool Designed to Help Patients Speak Up 57779 1 New Website Offers Free Tool Designed to Help Patients Speak Up 57779 2 Cadient Group Selected as Finalist in Medical Marketing 26 Media Awards 14180 1 Cadient Group Selected as Finalist in Medical Marketing 26 Media Awards 14180 2 Experimental drug lets B cells live and lymphoma cells die 57777 1 Experimental drug lets B cells live and lymphoma cells die 57777 2 Experimental drug lets B cells live and lymphoma cells die 57777 3 Experimental drug lets B cells live and lymphoma cells die 57777 4

[0] Healthcare Scoring System Allows Hospitals To Increase Charity Care [0] Accuray Incorporated to Present at 28th Annual J. P. Morgan Healthcare Conference [0] American Imaging Management's New Specialty Drug Program Delivers Immediate Results

... Patients Prefer Orapred ODT Over Liquid, ALPHARETTA, ... announced today survey results showing that,children prefer ... over liquid steroids.(1) , The results of ... children (n=973), showed that 89% (n=870) of ...

... /PRNewswire/ -- Portola,Pharmaceuticals, Inc. presented Phase I ... of Cardiology's (ACC) 56th Annual Scientific,Session this ... and well-tolerated in this study and,achieved high-level ... in a poster session titled "First in,Human ...

Other Medicine Technology:Orapred ODT Tastes Good 2 Orapred ODT Tastes Good 3 Portola Pharmaceuticals Presents Positive Phase I Data of Its ADP,Receptor Antagonist at the American College of Cardiology 2

Orapred ODT Tastes Good Portola Pharmaceuticals Presents Positive Phase I Data of Its ADP,Receptor Antagonist at the American College of Cardiology

(Date:12/16/2009)... is long-term goal, researchers say , , WEDNESDAY, Dec. ... to predict whether a patient will suffer a second ... "This is an important new tool because studies have ... after a first stroke are more likely to die ... General Hospital and Harvard Medical School, said in an ...

(Date:12/16/2009)... Institute announce the first comprehensive analyses of cancer genomes. ... the DNA of cancer cells which are acquired during ... and a lung cancer, reveal for the first time ... cancers. , Lung cancer causes around one million deaths ... The number of mutations found suggest that a typical ...

(Date:12/16/2009)... essential fatty acids commonly found in fatty fish ... to research published by the American Psychological Association. ... problems found in people with schizophrenia; bipolar, obsessive-compulsive, ... afflictions of the nervous system. , The ... , provides more evidence that fish is brain ...

(Date:12/16/2009)... half, but use in humans is still far off , , ... nature, researchers have built and tested synthetic versions of the ... other cases where blood just won,t stop flowing. , "We ... in degradable stitches, which dissolve in the body," said Erin ... Reserve University, and lead author of a report published ...

(Date:12/16/2009)... Specific Neurological Stress Reduction Therapy or NSRTSM is found very ... conditions such as allergies, asthma, migraines, chronic fatigue and a ... throughout the country are using this holistic therapy including over ... ... Minneapolis, MN (Vocus) December 14, 2009 -- ...

Breaking Medicine News(10 mins):Health News:New Stroke Tool May Predict Early Recurrence 2 Health News:Lung cancer and melanoma laid bare 2 Health News:Lung cancer and melanoma laid bare 3 Health News:Lung cancer and melanoma laid bare 4 Health News:Lung cancer and melanoma laid bare 5 Health News:Lung cancer and melanoma laid bare 6 Health News:New study links DHA type of omega-3 to better nervous-system function 2 Health News:Synthetic Platelets Put the Brakes on Blood Loss 2 Health News:Synthetic Platelets Put the Brakes on Blood Loss 3 Health News:BioVeda Health and Wellness Center of Chanhassen, MN Announces Its Grand Opening 2 Health News:BioVeda Health and Wellness Center of Chanhassen, MN Announces Its Grand Opening 3 Health News:BioVeda Health and Wellness Center of Chanhassen, MN Announces Its Grand Opening 4 Health News:BioVeda Health and Wellness Center of Chanhassen, MN Announces Its Grand Opening 5

[0] New Stroke Tool May Predict Early Recurrence [1] Lung cancer and melanoma laid bare [0] New study links DHA type of omega-3 to better nervous-system function [0] Synthetic Platelets Put the Brakes on Blood Loss [0] BioVeda Health and Wellness Center of Chanhassen, MN Announces Its Grand Opening

... of binge drinking in the UK rise, doctors in this ... who attended hospital with lower abdominal pain. , Although rare, ... excessive alcohol intake. , Alcohol misuse is costing the NHS ... cause by alcohol dependence or poisoning and 22,000 premature deaths ...

... Lanier, winner of nation,s first Vioxx trial, hails settlement as ,the ... ... The Lanier Law Firm are,announcing a nationwide settlement agreement with pharmaceutical giant,Merck ... 85% of the,personal injury lawsuits in the U.S. over Vioxx, the company,s,controversial ...

... ... ... Sunrise Senior Living,Inc. (NYSE: SRZ ) today reported preliminary selected ... also,provided preliminary information on recapitalizations, asset sales and,anticipated pre- tax charges and ...

... SOMERSET, N.J., Nov. 9 inVentiv Health Inc.,(Nasdaq: ... a new Client Development,and Integration team. The team will ... Chief Client Development Officer. The Client Development and ... segments to identify new opportunities to,serve both new and ...

... employees under a ,Pay or Play, law, 10,entry-level employees ... A new study presented as,part of a Cornell University ... to provide health insurance to their employees or a ... of the work,force., The study sponsored by the ...

... People who do not have HIV but seek ... likely to complete the full monthlong drug regimen, ... Moreover, there is a strong demand for publicly ... Angeles County. , Based on these findings, the ...

Warning for women who binge drink The Lanier Law Firm Announces $4.85 Billion National Vioxx Settlement With Merck & Co. Inc.Sunrise Reports Preliminary Selected Financial and Operating Data for Third-Quarter 2007 inVentiv Health Creates Client Development and Integration Team New Study: Health Insurance Mandates on Employers Hurt Low-Income Employees Study finds strong demand for HIV meds after high-risk sex

... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...

... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...

... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...

Medicine Products:

Immunoglobulin M, Serum Immunoglobulin G, Serum Immunoglobulin G Subclass 2 Immunoglobulin A, Serum

Excellent Results Received from GeoVax's Full-Dose HIV/AIDS Vac...( ATLANTA Nov. 2 /- GeoVax Labs Inc...),Health